Research programme: neurodegenerative disorder therapeutics - NeuroProfile
Latest Information Update: 11 Aug 2016
At a glance
- Originator NeuroProfile
- Mechanism of Action Neuron modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Parkinson's disease
Most Recent Events
- 11 Aug 2016 Preclinical trials in Parkinson's disease in Germany (unspecified route)
- 11 Aug 2016 Preclinical trials in Alzheimer's disease in Germany (unspecified route)